Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

IOVA

Iovance Biotherapeutics Inc

Feb 14 • 04:00PM ET

5.57

Dollar change +0.23
Percentage change 4.31	%

Healthcare • Biotechnology • USA • NASD

Peers: BMRN FATE CARA PRTA CRSP EDIT SGMO QURE ADAP NTLA

| Held by: VTI VB IWM VBR XBI VXF IWO VTWO IBB SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.50	Insider Own	18.99%	Shs Outstand	304.62M	Perf Week	-2.11%
Market Cap	1.70B	Forward P/E	-	EPS next Y	-0.87	Insider Trans	-0.09%	Shs Float	246.97M	Perf Month	-5.75%
Income	-410.00M	PEG	-	EPS next Q	-0.27	Inst Own	69.72%	Short Float	25.88%	Perf Quarter	-42.52%
Sales	90.86M	P/S	18.68	EPS this Y	31.48%	Inst Trans	3.16%	Short Ratio	8.30	Perf Half Y	-44.91%
Book/sh	2.54	P/B	2.19	EPS next Y	32.78%	ROA	-44.48%	Short Interest	63.91M	Perf Year	-39.19%
Cash/sh	1.30	P/C	4.27	EPS next 5Y	45.45%	ROE	-56.65%	52W Range	5.05 - 18.33	Perf YTD	-24.73%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-8.25%	ROI	-48.76%	52W High	-69.61%	Beta	0.89
Dividend TTM	-	Quick Ratio	3.90	Sales past 5Y	0.00%	Gross Margin	-19.74%	52W Low	10.30%	ATR (14)	0.38
Dividend Ex-Date	-	Current Ratio	4.22	EPS Y/Y TTM	28.07%	Oper. Margin	-473.22%	RSI (14)	38.61	Volatility	6.59% 5.95%
Employees	557	Debt/Eq	0.10	Sales Y/Y TTM	12751.20%	Profit Margin	-451.25%	Recom	1.40	Target Price	23.50
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	40.47%	Payout	-	Rel Volume	1.06	Prev Close	5.34
Sales Surprise	8.87%	EPS Surprise	6.32%	Sales Q/Q	12385.07%	Earnings	Nov 07 AMC	Avg Volume	7.70M	Price	5.57
SMA20	-4.60%	SMA50	-18.77%	SMA200	-37.99%	Trades		Volume	8,126,619	Change	4.31%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-24-24	Initiated	UBS	Buy	$17
Jul-29-24	Downgrade	Piper Sandler	Overweight → Neutral	$19 → $10
Nov-20-23	Initiated	Goldman	Buy	$12
Sep-18-23	Reiterated	Barclays	Overweight	$40 → $18
May-30-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$11 → $17
Mar-27-23	Resumed	Wells Fargo	Equal Weight	$11
Jan-27-23	Upgrade	Piper Sandler	Neutral → Overweight	$11 → $14
Dec-09-22	Downgrade	Goldman	Buy → Neutral	$20 → $6
Oct-31-22	Initiated	Guggenheim	Neutral
Aug-18-22	Resumed	Wells Fargo	Equal Weight	$14
Jan-28-22	Upgrade	Stifel	Hold → Buy	$23 → $25
Dec-07-21	Resumed	Cowen	Outperform
Jun-10-21	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$32
May-20-21	Downgrade	Piper Sandler	Overweight → Neutral	$35 → $18
May-19-21	Downgrade	Stifel	Buy → Hold
May-19-21	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
May-03-21	Initiated	Truist	Buy	$50
Apr-16-21	Initiated	Goldman	Buy	$97
Mar-08-21	Upgrade	H.C. Wainwright	Neutral → Buy	$50
Dec-15-20	Downgrade	H.C. Wainwright	Buy → Neutral

Show Previous Ratings

Feb-12-25 05:30PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-10-25 07:00AM	Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer (GlobeNewswire) -6.50%
Jan-30-25 07:30AM	What's Wrong With Iovance Biotherapeutics Stock? (Motley Fool)
Jan-29-25 08:30AM	Where Will Iovance Biotherapeutics Be in 5 Years? (Motley Fool)
Jan-27-25 04:31AM	Meet the Growth Stock That Could Soar 280%, According to Wall Street Analysts (Motley Fool)
03:10PM	Loading…
Jan-20-25 03:10PM	Is Iovance Biotherapeutics (IOVA) Among Billionaire Joseph Edelmans Long-Term Stock Picks? (Insider Monkey)
Jan-18-25 06:50PM	3 Stocks That Could Turn $1,000 Into $5,000 by 2030 (Motley Fool)
Jan-17-25 05:00PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-09-25 04:20AM	3 Mid-Cap Stocks That Could Take Off in 2025 (Motley Fool)
Jan-02-25 07:03PM	Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today (Motley Fool) +5.27%
03:24AM	Why Iovance Biotherapeutics Inc. (IOVA) Is Skyrocketing (Insider Monkey)
Dec-20-24 05:00PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-19-24 04:02AM	If I Could Only Buy 3 Stocks in the Last Month of 2024, I'd Pick These (Motley Fool)
Dec-17-24 05:29AM	2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio? (Motley Fool)
Dec-12-24 10:00AM	Prediction: This Stock Will Beat the Market in 2025 (Motley Fool) -7.23%
11:08AM	Loading…
Dec-07-24 11:08AM	3 Monster Stocks to Hold for the Next 10 Years (Motley Fool)
Nov-27-24 06:30AM	Is Iovance Biotherapeutics Stock a Millionaire Maker? (Motley Fool)
Nov-26-24 04:01PM	Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer (GlobeNewswire)
Nov-23-24 11:35AM	Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back (Motley Fool)
10:31AM	Iovance Biotherapeutics, Inc. (IOVA): Among the Most Promising Cancer Stocks According to Hedge Funds (Insider Monkey)
Nov-22-24 10:00AM	2 Innovative Stocks That Could Deliver Outsize Returns (Motley Fool)
07:49AM	Iovance Biotherapeutics Inc. (IOVA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Nov-14-24 08:00AM	Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon (PR Newswire)
Nov-08-24 08:03AM	Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlights: Surpassing Revenue ... (GuruFocus.com) -13.80%
Nov-07-24 05:45PM	Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:42PM	Iovance Biotherapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024 (GlobeNewswire)
Oct-31-24 04:01PM	Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024 (GlobeNewswire) -5.43% +7.18%
Oct-24-24 06:01PM	Why Iovance Biotherapeutics Stock Triumphed on Thursday (Motley Fool) +7.54%
Oct-18-24 11:01AM	State Street Corp's Strategic Acquisition in Iovance Biotherapeutics Inc (GuruFocus.com)
07:15PM	Loading…
Oct-16-24 07:15PM	Is Iovance Biotherapeutics Inc. (IOVA) the Most Promising Stock to Buy According to Wall Street Analysts? (Insider Monkey) +8.54%
Oct-12-24 12:28PM	Is Iovance Biotherapeutics, Inc. (IOVA) the Best Growth Stock Under $10 to Buy? (Insider Monkey)
Oct-10-24 10:39AM	Is Iovance Biotherapeutics, Inc. (IOVA) the Best Stock Under $10 With High Potential? (Insider Monkey)
Oct-09-24 08:03AM	Strong Investor Sentiment: Artisan Partners Highlights Iovance Biotherapeutics, Inc. (IOVA) (Insider Monkey)
Oct-04-24 08:30AM	Is Iovance Biotherapeutics Stock a Buy? (Motley Fool) +7.17%
Sep-26-24 08:15AM	3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow (Motley Fool)
Sep-16-24 06:29AM	3 Things You Need to Know if You Buy Iovance Biotherapeutics Today (Motley Fool) -5.13%
Sep-14-24 05:32PM	Iovance Biotherapeutics, Inc. (IOVA): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
Sep-06-24 09:30AM	This Is the Biggest Risk With Iovance Biotherapeutics Stock (Motley Fool)
Sep-03-24 05:00PM	Iovance Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire) -6.95%
Sep-02-24 06:15PM	3 Monster Biotech Stocks to Buy Before 2025 (Motley Fool)
Aug-27-24 04:36AM	Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years? (Motley Fool)
Aug-16-24 05:00PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +6.57%
Aug-14-24 07:15AM	This 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics Stock (Motley Fool) -5.87%
Aug-09-24 12:23PM	Why Iovance Biotherapeutics Shares Are Soaring Today (Motley Fool) +24.94%
09:27AM	Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View (Zacks)
Aug-08-24 05:30PM	Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.32%
04:24PM	Iovance Biotherapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024 (GlobeNewswire)
Aug-01-24 10:01AM	Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -6.53%
Jul-31-24 05:31AM	Iovance Biotherapeutics Attracted a Downgrade. Is It Time to Sell? (Motley Fool)
Jul-29-24 06:24PM	Why Iovance Biotherapeutics Stock Stumbled Today (Motley Fool)
04:01PM	Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024 (GlobeNewswire)
08:31AM	Heres Why Iovance Biotherapeutics (IOVA) Declined in Q2 (Insider Monkey)
Jul-19-24 05:00PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-17-24 02:29PM	7 Death Cross Stocks That Could Be Contrarian Buys (InvestorPlace)
Jul-14-24 05:45AM	Is Iovance Biotherapeutics a Millionaire Maker? (Motley Fool)
Jul-11-24 02:23PM	3 Under-$10 Biotech Stocks That Could Make You Rich (InvestorPlace) +8.48%
Jul-08-24 06:46PM	Is Iovance Biotherapeutics, Inc. (IOVA) One of the Most Shorted Stocks Loved by Analysts? (Insider Monkey)
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jun-28-24 07:00AM	Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma (GlobeNewswire)
04:05AM	Is It Too Late to Buy Iovance Biotherapeutics Stock? (Motley Fool)
Jun-21-24 05:00PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
06:36AM	3 Top Penny Stocks to Skyrocket Your Wealth in 2024 (InvestorPlace)
Jun-20-24 10:02PM	Is WSJ the Best Stock Analysis Website? (Insider Monkey)
08:47PM	15 Best Websites To Research Stocks (Insider Monkey)
Jun-10-24 10:15AM	The Case for Buying Iovance Biotherapeutics Stock Just Got Even Better. Here's Why (Motley Fool)
May-29-24 06:20AM	What Makes e.l.f. Beauty (ELF) an Investment Bet? (Insider Monkey)
04:58AM	Should You Consider Adding SharkNinja (SN) to Your Portfolio? (Insider Monkey)
May-28-24 08:14AM	Iovance Biotherapeutics (IOVA) Shares Rallied after the FDA approval of AMTAGVI (Insider Monkey)
08:06AM	Artisan Partners Small Cap Fund Trimmed Wingstop (WING) Based on Valuation Discipline (Insider Monkey)
May-24-24 04:01PM	Iovance Biotherapeutics to Present at Upcoming Conferences and Events (GlobeNewswire)
11:18AM	Iovance (IOVA) Up 5% on Updated Data From Melanoma Study (Zacks)
May-23-24 05:00PM	Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting (GlobeNewswire)
May-22-24 06:40AM	Bull Market Buys: 2 Growth Stocks to Own for the Long Run (Motley Fool)
May-17-24 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
May-16-24 09:30AM	4 Small-Cap Value Stocks That Could Go Parabolic (Motley Fool)
May-13-24 02:25PM	Truist Securities Trims Iovance Biotherapeutics' Price Target to $25 From $26, Buy Rating Maintained (MT Newswires)
12:42PM	Truist Adjusts Iovance Biotherapeutics' Price Target to $25 From $26, Keeps Buy Rating (MT Newswires)
May-11-24 10:00AM	The 3 Most Undervalued Biotech Stocks to Buy in May 2024 (InvestorPlace)
May-10-24 02:03PM	Why Iovance Stock Is Down 18% Today (Motley Fool) -18.48%
01:35PM	Iovance Biotherapeutics' Patient Selection for Amtagvi Launch Minimizing Attrition, Truist Securities Says (MT Newswires)
12:55PM	Iovance Biotherapeutics Inc (IOVA) Q1 2024 Earnings: Aligns with EPS Projections Amidst Strong ... (GuruFocus.com)
12:33PM	Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:25AM	Update: Iovance Biotherapeutics Shares Fall After Q1 Revenue Misses Estimates (MT Newswires)
10:58AM	Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates (Zacks)
May-09-24 08:57PM	IOVA Stock Earnings: Iovance Biotherapeutics Meets EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:27PM	Iovance Biotherapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:23PM	Iovance Biotherapeutics Q1 Loss Narrows -- Shares Higher After Hours (MT Newswires)
04:01PM	Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
May-06-24 09:56AM	Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect (Zacks)
May-01-24 06:01AM	Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024 (GlobeNewswire) +6.11%
Apr-30-24 06:01AM	Iovance Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire)
Apr-28-24 02:44PM	Where Will Iovance Biotherapeutics Stock Be in 5 Years? (Motley Fool)
Apr-27-24 07:00AM	The Top 3 Biotech Stocks to Buy in April 2024 (InvestorPlace)
Apr-25-24 10:30AM	3 Millionaire-Maker Biotech Stocks (Motley Fool)
09:20AM	20 Counties with the Highest Cancer Rates in the US (Insider Monkey)
Apr-24-24 04:01PM	Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-21-24 05:08AM	These Biotech Stocks Could Soar 120% and 295%, According to Wall Street (Motley Fool)
Apr-19-24 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vogt Frederick G	Interim CEO & General Counsel	Jan 14 '25	Option Exercise	0.00	20,835	0	231,071	Jan 16 06:01 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Jan 14 '25	Option Exercise	0.00	2,813	0	65,464	Jan 16 06:00 PM
BILINSKY IGOR	Chief Operating Officer	Jan 14 '25	Option Exercise	0.00	2,813	0	60,352	Jan 16 05:59 PM
Puri Raj K.	Chief Regulatory Officer	Dec 16 '24	Option Exercise	0.00	8,334	0	159,171	Dec 18 05:15 PM
Vogt Frederick G	Interim CEO & General Counsel	Dec 02 '24	Option Exercise	0.00	10,417	0	214,662	Dec 04 04:31 PM
BILINSKY IGOR	Chief Operating Officer	Dec 02 '24	Option Exercise	0.00	3,516	0	59,323	Dec 04 04:30 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Dec 02 '24	Option Exercise	0.00	3,906	0	64,633	Dec 04 04:30 PM
Maynard Ryan D	Director	Nov 12 '24	Option Exercise	7.45	50,000	372,500	57,500	Nov 14 05:00 PM
Maynard Ryan D	Director	Nov 12 '24	Sale	10.06	50,000	503,000	7,500	Nov 14 05:00 PM
Maynard Ryan D	Director	Nov 12 '24	Proposed Sale	10.06	50,000	503,104		Nov 12 07:11 PM
Vogt Frederick G	Interim CEO & General Counsel	Oct 14 '24	Option Exercise	0.00	20,834	0	213,096	Oct 16 06:33 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Oct 14 '24	Option Exercise	0.00	2,813	0	62,155	Oct 16 06:32 PM
BILINSKY IGOR	Chief Operating Officer	Oct 14 '24	Option Exercise	0.00	2,813	0	57,235	Oct 16 06:30 PM
Vogt Frederick G	Interim CEO & General Counsel	Sep 03 '24	Option Exercise	0.00	57,292	0	212,175	Sep 05 07:56 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Sep 03 '24	Option Exercise	0.00	27,345	0	71,233	Sep 05 07:54 PM
BILINSKY IGOR	Chief Operating Officer	Sep 03 '24	Option Exercise	0.00	26,954	0	66,313	Sep 05 07:53 PM
Bellemin Jean-Marc	Chief Financial Officer	Sep 03 '24	Option Exercise	0.00	23,438	0	41,239	Sep 05 07:52 PM
Vogt Frederick G	Interim CEO & General Counsel	Jul 15 '24	Option Exercise	0.00	20,835	0	168,160	Jul 17 08:01 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Jul 15 '24	Option Exercise	0.00	2,813	0	47,299	Jul 17 08:01 PM
BILINSKY IGOR	Chief Operating Officer	Jul 15 '24	Option Exercise	0.00	2,813	0	42,571	Jul 17 08:00 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Jun 03 '24	Option Exercise	0.00	3,906	0	46,468	Jun 05 08:07 PM
BILINSKY IGOR	Chief Operating Officer	Jun 03 '24	Option Exercise	0.00	3,516	0	41,542	Jun 05 08:05 PM
Vogt Frederick G	Interim CEO & General Counsel	Jun 03 '24	Option Exercise	0.00	10,417	0	151,751	Jun 05 08:04 PM
Vogt Frederick G	Interim CEO & General Counsel	Apr 15 '24	Option Exercise	0.00	20,834	0	150,185	Apr 17 07:08 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Apr 15 '24	Option Exercise	0.00	2,812	0	43,989	Apr 17 07:07 PM
BILINSKY IGOR	Chief Operating Officer	Apr 15 '24	Option Exercise	0.00	2,812	0	39,453	Apr 17 07:07 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Mar 04 '24	Option Exercise	0.00	15,623	0	49,230	Mar 06 06:20 PM
Vogt Frederick G	Interim CEO & General Counsel	Mar 04 '24	Option Exercise	0.00	41,662	0	140,800	Mar 06 06:19 PM
MCPEAK MERRILL A	Director	Feb 20 '24	Buy	9.15	250,000	2,287,500	320,150	Feb 20 07:52 PM
Dukes Iain D.	Director	Feb 20 '24	Buy	9.15	32,000	292,800	54,000	Feb 20 04:21 PM
Rothbaum Wayne P.	Director	Feb 20 '24	Buy	9.15	5,000,000	45,750,000	28,067,333	Feb 20 04:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IOVA

Iovance Biotherapeutics Inc

Upgrade your FINVIZ experience